Atomo Diagnostics MD & CEO Delivers FY26 AGM Address with HIV Test Volume and OEM Revenue Disclosed

Sonal Goyal

05 November 2026 03:14 PM AEDT

Atomo Diagnostics MD & CEO Delivers FY26 AGM Address with HIV Test Volume and OEM Revenue Disclosed

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Atomo Diagnostics (ASX:AT1) has released the Managing Director and CEO's address delivered at the company's 2026 Annual General Meeting on 5 November 2026, disclosing operational data including HIV Gen 3 unit growth of 21% year-on-year in FY26 and OEM revenue growth of 209% year-on-year in FY26.

Key Points

HIV Gen 3 franchise recorded plus 21% year-on-year growth in FY26, with more than 5 million tests supplied across 30-plus countries.
OEM revenue grew 209% year-on-year in FY26, driven by the FebriDx product.
FebriDx had 215 live US sites recorded in Q1 FY27.
Partner pipeline includes pregnancy (commercial stage), and ferritin and pre-hospital stroke products currently in validation.

HIV Franchise and Proprietary Product Performance

According to the AGM presentation, Atomo's HIV Gen 3 franchise recorded growth of 21% year-on-year in FY26, with more than 5 million tests supplied across more than 30 countries. The company described its proprietary products as blood-based rapid tests sold globally through professional and self-test channels. The growing pipeline for proprietary products includes a Gen 4 HIV test, an Active Syphilis test, and a Liver/ALT test. The company stated its patented all-in-one blood collection solutions are designed for usability, reliability and performance in decentralised testing environments.

OEM Business and FebriDx Commercial Expansion

The filing disclosed that OEM revenue increased 209% year-on-year in FY26, with FebriDx identified as the primary driver of that growth. As of the first quarter of FY27, 215 live US sites were operating with FebriDx. Atomo described its point-of-care technologies and OEM segment as offering integrated all-in-one and modular devices designed to help partners improve the usability and performance of blood-based tests. The partner pipeline at the time of the presentation included a pregnancy product at a commercial stage, with ferritin and pre-hospital stroke products remaining in validation.

Device Platforms and Company Mission

The AGM presentation outlined two device platforms disclosed by Atomo. The Pascal platform was described as an integrated all-in-one configuration featuring a built-in auto-retracting safety lancet, button-activated buffer delivery, and interlocked steps, with the company citing 99% concordance between professional and non-professional users. The Galileo platform was also referenced as a streamlined offering. The company stated its mission as putting the user experience at the centre of diagnostics, expanding equitable and affordable access to accurate diagnosis and a seamless pathway to treatment. The AGM address was authorised by the Managing Director and CEO on behalf of the Board.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.